1. Home
  2. |Insights
  3. |And Then There Was One... GSA Schedule

And Then There Was One... GSA Schedule

Client Alert | 1 min read | 11.28.18

The General Services Administration announced yesterday that it will consolidate the agency’s 24 Multiple Award Schedules into one single Federal Supply Schedule that includes both products and services. Through this consolidation, which GSA anticipates will take two years through a phased approach, the GSA intends to ease the process of purchasing for government customers, allowing for greater flexibility to combine products and services into a single combined solution. For government contractors, this combination is expected to ease the administrative burden associated with holding more than one schedule for multiple lines of businesses including products and/or services. We expect there will be more information in the coming months on this major reform; the GSA has already announced an industry day on December 12 from 9:30 – 2:45 EST when the consolidation will be discussed more broadly.

Contacts

Insights

Client Alert | 7 min read | 09.14.26

AI in Life Sciences: Ten Legal Considerations and Risks of AI Use in Drug Discovery and Development

Over the past several years, the biopharmaceutical industry has embraced artificial intelligence and machine learning (AI/ML) in near lockstep with the pace of AI/ML innovations. Today, industry leaders are using AI/ML to, among other things: discover and assess biological pathways, target chemical structures and sequences; design proteins; model pre-clinical and clinical trials; recruit and screen potential patient populations; evaluate clinical trial results and biomarker data; prepare regulatory filings; and manage supply chains. Deployment of new AI/ML models promises extraordinary advances in pharmaceutical development. However, as with any technological and scientific advances, the use of AI/ML also poses substantial legal risks that life sciences companies need to consider and proactively manage. ...